The Food and Drug Administration (FDA) announced yesterday the first approved nasal-spray version of naloxone hydrochloride, a medication that can stop or reverse the effects of an opioid overdose. The agency granted fast-track designation and priority review for the nasal spray – previously the drug was only approved in injectable forms, limiting its use. The FDA reiterated that although nasal naloxone is a key tool, reviving an overdose victim with naloxone only provides an opportunity to seek emergency medical care. It can also trigger severe withdrawal symptoms for addicts.
Read the announcement in full here.